Swedish Orphan Biovitrum

Stockholm, Sweden
Invested through
  • Triodos Future Generations Fund
  • Triodos Impact Strategy Fund - Defensive
  • Triodos Impact Strategy Fund - Balanced
  • Triodos Impact Strategy Fund - Offensive
  • Triodos Impact Strategy Fund - Dynamic
Asset ClassesListed equity
Impact strategyImpact Equities and Bonds
ISIN codeSE0000872095
Industry grouphealthcare
Aligned with SDGs
  • Good health and well-being

Swedish Orphan Biovitrum (SOBI) is a biopharmaceutical company focused on rare diseases. It has three business divisions related to the therapeutic areas it serves: Haematology (area of medicine dealing with diseases of the blood), Immunology (enabling the treatment of serious, disabling or even life-threatening diseases), and Specialty Care (providing products for the treatment of genetic and metabolic diseases). The company develops therapies and medicines for the treatment of rare diseases. SOBI distributes its treatments in more than 70 countries and has approximately 1,600 employees globally, with offices in more than 30 countries.

Investment rationale

SOBI focuses on developing treatments referred to as 'orphan drugs', intended to treat diseases so rare that traditional pharmaceutical companies would be reluctant to develop them under normal market conditions. Thanks to this focus the company helps to improve the lives of people living with rare diseases, which have great unmet medical needs. The company also donates medicines in underserved regions by supporting the World Federation of Haemophilia (WFH) Humanitarian Aid Program with donations of millions of international units (IU) of factor therapy for humanitarian use. Based on the positive impact of improving the life of people living with rare diseases and its contribution to improving access to treatment of these diseases, SOBI aligns with our Prosperous and Healthy People investment theme.